Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension

No abstract is available for this paper.

• Publication year

  2020

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2020-06-25

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00228-020-02937-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome

  2019cited by this paper
• Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease

  2018cited by this paper
• The Real Role of β-Blockers in Daily Cardiovascular Therapy

  2017cited by this paper
• Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation

  2017cited by this paper
• Population Pharmacokinetics of Bisoprolol in Hemodialysis Patients with Hypertension

  2016cited by this paper
• Structural and Functional Changes With the Aging Kidney.

  2016cited by this paper
• Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study

  2016cited by this paper
• Population pharmacokinetics of 25-hydroxyvitamin D in healthy young adults.

  2015cited by this paper
• Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis.

  2015cited by this paper
• Body Composition in Type 2 Diabetes: Change in Quality and not Just Quantity that Matters

  2015cited by this paper
• Estimated glomerular filtration rate in patients with type 2 diabetes mellitus.

  2014cited by this paper
• Guidelines for the management of arterial hypertension

  2014cited by this paper
• The current status of beta blockers’ use in the management of hypertension

  2014cited by this paper
• New advances in beta-blocker therapy in heart failure

  2013cited by this paper
• Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs

  2012cited by this paper
• Population pharmacokinetics of bisoprolol in patients with chronic heart failure

  2012cited by this paper
• Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus

  2011cited by this paper
• Population pharmacokinetics of lamotrigine in patients with epilepsy.

  2009cited by this paper
• Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells.

  2008cited by this paper
• Are we misunderstanding beta-blockers.

  2007cited by this paper
• 2013 ESH/ESC Guidelines for the management of arterial hypertension

  2007cited by this paper
• Bisoprolol in the treatment of chronic heart failure

  2007cited by this paper
• Stereoselective interaction of manidipine and grapefruit juice: a new twist on an old tale.

  2006cited by this paper
• Influence of CYP2D6 Genotype on Metoprolol Plasma Concentration and β-Adrenergic Inhibition During Long-Term Treatment: A Comparison With Bisoprolol

  2005cited by this paper
• Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients.

  2005cited by this paper
• Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers

  2004cited by this paper
• TWO MAJOR GRAPEFRUIT JUICE COMPONENTS DIFFER IN INTESTINAL CYP3A4 INHIBITION KINETIC AND BINDING PROPERTIES

  2004cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• The kidney in hypertension.

  2001cited by this paper
• Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin

  2000cited by this paper
• Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology

  1999cited by this paper
• Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice.

  1999cited by this paper
• Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.

  1998cited by this paper
• Hyperinsulinemia, insulin resistance, and the treatment of hypertension.

  1996cited by this paper
• Long-term metabolic effects of antihypertensive drugs.

  1994cited by this paper
• Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

  1991cited by this paper
• Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.

  1990cited by this paper
• [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].

  1990cited by this paper
• Clinical use of beta-adrenoceptor blockade in systemic hypertension.

  1990cited by this paper
• [Liver cirrhosis].

  1989cited by this paper
• Population Pharmacokinetic Analysis of Bisoprolol

  1989cited by this paper
• Pharmacokinetics of Bisoprolol During Repeated Oral Administration to Healthy Volunteers and Patients with Kidney or Liver Disease

  1987cited by this paper

• No citing papers are available for this paper.